MoonLake Immunotherapeutics

MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company dedicated to optimizing and accelerating the development of the product pipeline for Sonelokimab, a potentially best-in-class trispecific Nanobody®. Sonelokimab has clinically proven potential to improve disease treatment for patients with dermatological and rheumatic conditions.